Showing 8401-8410 of 9130 results for "".
- FDA Approves Poteligeo for Cutaneous T-Cell Lymphomashttps://practicaldermatology.com/news/fda-approves-poteligeo-for-cutaneous-t-cell-lymphomas/2457657/The FDA approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with two types of cutaneous T-cell lymphoma (CTCL)—relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. This a
- Plastic Surgery Groups Issue Warning on the Risks of Brazilian Butt Liftshttps://practicaldermatology.com/news/plastic-surgery-groups-issue-warning-on-the-risks-of-brazilian-butt-lifts/2457659/Leading plastic surgery organizations are issuing a loud warning call about the risks associated with the popular Brazilian Butt Lift. “[The] procedure … has resulted in a mortality rate that is estimated to be as high as 1:3,000, greater than any other cosmetic surgery,&rdqu
- Almirall to Acquire Allergan's US Medical Dermatology Unithttps://practicaldermatology.com/news/almirall-to-acquire-allergans-us-medical-dermatology-unit/2457661/Almirall is acquiring a portfolio of five products from Allergan’s Medical Dermatology unit in the United States, conditional to the clearance by the relevant authorities. The portfolio includes Aczone® (dapsone), Tazorac® (tazarotene), Azelex® (azelaic acid) and Cordran® Ta
- IRB Approval Means BioPharmX To Move Ahead on Phase 2 Trial of BPX-04 for Rosaceahttps://practicaldermatology.com/news/irb-approval-means-biopharmx-to-move-ahead-on-phase-2-trial-of-bpx-04-for-rosacea/2457665/BioPharmX Corporation has received Institutional Review Board approval for its phase 2 study of BPX-04 for the treatment of papulopustular rosacea. Based on data from its open-label feasibility study which assessed tolera
- LEO Pharma to Acquire Bayer Prescription Dermatology Businesshttps://practicaldermatology.com/news/leo-pharma-to-acquire-bayer-prescription-dermatology-business/2457666/LEO Pharma has entered into a definitive agreement to buy Bayer's global prescription dermatology unit. The portfolio to be acquired includes branded topical prescription treatments for acne, fungal skin infections, and rosacea and a range of topical steroids with an annual turnover in 2017 o
- Consensus: Straight-Line Vector Planning Produces Best Silhouette InstaLift Resultshttps://practicaldermatology.com/news/consensus-straight-line-vector-planning-produces-best-silhouette-instalift-results/2457668/Straight-line vector planning produces the ideal lifting effect and sets the stage for maximum collagen regeneration with the Silhouette InstaLift, according to a study in the July 2018 issue of Journal of Drugs in Dermat
- TruDerm Adds Second Dermatology Centerhttps://practicaldermatology.com/news/truderm-adds-second-dermatology-center/2457681/
- Game On: Head-to-head Trials to Enhance Competition in PsO Markethttps://practicaldermatology.com/news/head-to-head-trials-to-enhance-competition-in-pso-market/2457684/An increase in head-to-head trials will enhance the competition within the psoriasis market, according to
- AMSPA Merges with IALAhttps://practicaldermatology.com/news/amspa-merges-with-iala/2457688/The American Med Spa Association (AmSpa) is merging with the International Aesthetic and Laser Association, Inc. (IALA). The
- Dermatologists, Skin Cancer Survivors Tell "Skin Cancers, Take a Hike!"https://practicaldermatology.com/news/dermatologists-skin-cancer-survivors-tell-skin-cancers-take-a-hike/2457695/To help raise awareness of skin cancer prevention and detection, 12 dermatologists, skin cancer survivors, and their family and friends will tell “Skin Cancer, Take a Hike!” during a four-day trek through remote Alaska. Starting Sunday, July 15, the hikers will trek more than 20 miles